EDGAR Filing Documents for 0001104659-21-029283

Form 8-K - Current report:

SEC Accession No. 0001104659-21-029283

Filing Date

2021-02-26

Accepted

2021-02-26 16:41:11

Documents

Period of Report

2021-02-24

Items

Item 2.02: Results of Operations and Financial Condition
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Interactive Data

Document Format Files

Seq	Description	Document	Type	Size
1	FORM 8-K	tm217918d1_8k.htm iXBRL	8-K	38464
2	EXHIBIT 99.1	tm217918d1_ex99-1.htm	EX-99.1	10650
	Complete submission text file	0001104659-21-029283.txt		231717

Data Files

Seq	Description	Document	Type	Size
3	XBRL TAXONOMY EXTENSION SCHEMA	nbrv-20210224.xsd	EX-101.SCH	3184
4	XBRL TAXONOMY EXTENSION LABEL LINKBASE	nbrv-20210224_lab.xml	EX-101.LAB	34592
5	XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE	nbrv-20210224_pre.xml	EX-101.PRE	22709
6	EXTRACTED XBRL INSTANCE DOCUMENT	tm217918d1_8k_htm.xml	XML	3636

Mailing Address 1000 CONTINENTAL DRIVE SUITE 600 KING OF PRUSSIA PA 19406

Business Address 56 FITZWILLIAM SQUARE DUBLIN L2 2 (610) 816-6640

Nabriva Therapeutics plc (Filer) CIK: 0001641640 (see all company filings)